Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURE methotrexate study in recurrent differentiated vulvar intraepithelial neoplasia
NL-OMON61076Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methotrexate in differentiated vulvar intraepithelial neoplasia (dVIN) and Kraurosis vulvae, sponsored by Amsterdam University Medical Center. Primary endpoints: Time to recurrence of differentiated vulvar intraepithelial neoplasia and Clinical response status. Started Aug 2026; status: recruiting.
02
Drugs
methotrexate
03
Conditions
differentiated vulvar intraepithelial neoplasia (dVIN)Kraurosis vulvae
Beyond the preview
Go deeper on NL-OMON61076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61076.